MDX — Medx Health Income Statement
0.000.00%
- CA$17.51m
- CA$23.73m
- CA$0.46m
Annual income statement for Medx Health, fiscal year end - December 31st, CAD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | C2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0.86 | 0.53 | 0.563 | 0.511 | 0.456 |
Cost of Revenue | |||||
Gross Profit | 0.48 | 0.268 | 0.273 | 0.24 | 0.186 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 4.14 | 3.73 | 5.89 | 5.64 | 5.04 |
Operating Profit | -3.28 | -3.2 | -5.32 | -5.13 | -4.58 |
Net Income Before Taxes | -3.28 | -3.2 | -5.32 | -5.13 | -4.58 |
Net Income After Taxes | -3.28 | -3.2 | -5.32 | -5.13 | -4.58 |
Net Income Before Extraordinary Items | |||||
Net Income | -3.28 | -3.2 | -5.32 | -5.13 | -4.58 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -3.28 | -3.2 | -5.32 | -5.13 | -4.58 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.023 | -0.019 | -0.03 | -0.028 | -0.026 |